Fresh analysis indicates that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight far faster than those who halt traditional diet and exercise regimens.
Research printed in a prominent medical journal demonstrates that while overweight people often shed about a fifth of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying these drugs must be informed of the potential of quick weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment mass in about 18 months.
Weighing Therapies
The analysis, which examined 37 of studies involving over 9,000 of participants, compared the results of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through dieting typically have a slower creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Nutrition scientists suggest the way of the injections is key to understanding the amplified regain.
The injections mimic a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication leads to appetite is uncontrolled, making binge eating much more probable."
An Ongoing Condition?
Medical guidelines advise the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the significant potential of weight regain, the therapy is often ongoing.
This view is supported by drug manufacturers, who state that the results "highlight the long-term nature of excess weight," akin to managing conditions like hypertension.
User Testimonies
Individuals who have come off the jabs report a intense return of appetite.
"I experienced a switch activating and you become starving," said one woman.
This difficulty is worsened if patients have not established sustainable dietary or behavioural modifications during treatment.
Growing Interest
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent solution and maintained weight loss relies on combined lifestyle support.
